Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trityl Imidazole SCHEMBL1572623 | 0.89 | MTOR (0.45) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL7182199 | 0.86 | CYP19A1 (0.36) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL11089506 | 0.86 | MTOR (0.45) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL5738213 | 0.83 | NISCH (0.43) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL3827055 | 0.83 | CYP19A1 (0.41) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL15263039 | 0.83 | CYP19A1 (0.61) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL11863057 | 0.80 | CYP19A1 (0.61) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL11863803 | 0.80 | CYP19A1 (0.41) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL7802984 | 0.80 | CYP19A1 (0.42) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL7819462 | 0.80 | CYP19A1 (0.39) | CYP19A1MTORADKNISCHTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0695748-B1 | Tetrazolinone herbicides | BAYER AGROCHEM KK (JP) | 1999-05-06 | — | — | EP | claimed |
| EP-3999183-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Ono Pharmaceutical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021010492-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-21 | — | — | WO | disclosed |
| EP-3366678-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | Newlink Genetics Corporation (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2976332-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION. | NEWLINK GENETICS CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3145944-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-3008042-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | Orion Corporation (FI) | 2016-04-20 | — | — | EP | disclosed |
| EP-0891343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5859035-A | Arylheteroaryl inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854265-A | Biheteroaryl inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1997036605-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036897-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036585-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036900-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036875-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036886-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036881-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | IDO1, IDO2, TDO2 | CYP19A1 639/4885MTOR 280/4885ADK 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.